Chromadex Corp

Chromadex Corp(CDXC)股票分析

$7.870

-0.069 (-0.88%)收盘时

Loading chart…
High
7.920
Open
7.910
VWAP
7.84
Vol
554.83K
Mkt Cap
Low
7.745
Amount
4.35M
EV/EBITDA, TTM
32.82

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Analyst Ratings (2)

Buy
2 Buy
0 Hold
0 Sell
Current: 7.87
最低
平均
最高

HC Wainwright & Co.

2025-04-08

目标价

$11

Strong Buy

HC Wainwright & Co.

2025-03-31

目标价

$11

Strong Buy

HC Wainwright & Co.

2025-03-17

目标价

$11

Strong Buy

HC Wainwright & Co.

2025-03-10

目标价

$11

Strong Buy

Ladenburg Thalmann

2025-03-05

目标价

$8.1

Strong Buy

估值指标

The current forward P/E ratio for Chromadex Corp (CDXC) is 66.04, compared to its 5-year average forward P/E of 44.66.

Forward P/E

Fair
5Y Average P/E
44.66
Current P/E
66.04
高估
179.74
低估
-90.42

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
34.78
Current EV/EBITDA
32.82
高估
101.31
低估
-31.75

Forward P/S

Overvalued
5Y Average P/S
2.26
Current P/S
3.62
高估
3.52
低估
1.00

CDXC FAQ — answered by Alphio AI

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

2 analysts cover CDXC: 2 rate it Buy, 0 Hold and 0 Sell.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始